| Ytd | -64.66% | |
| 1y | -27.66% |
| Open | 5.30 | Prev Close | 5.36 | Low | 5.05 | High | 5.33 | Mkt Cap | 10.24M |
| Vol | 7.89K | Avg Vol | 241.38K | EPS | -29.56 | P/E | -0.17 | Forward P/E | -0.43 |
| Beta | 1.50 | Short Ratio | 0.20 | Inst. Own | 5.89% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 4.47 | 200-d Avg | 8.52 | 1yr Est | 4.50 |
QNRX News
ASHBURN, Va., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Comp
Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) shares moved upwards by 41.1% to $0.09 during Frida
Quoin Pharmaceuticals (NASDAQ: QNRX) receives FDA IND clearance for a Phase 2 study of QRX003 in Pee
ASHBURN, Va., June 30, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd.
Gainers Pulsenmore (NASDAQ:PLSM) stock increased by 152.0% to $8.59 during Wednesday's pre-mark
Leifras Co Ltd (NASDAQ: LFS) rose in pre-market trading after acquiring SWIFT JAPAN for JPY454.6 mil
Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 40.3% to $4.56 during Tuesday's after-m
QRX003 Holds Orphan Drug Designation in the United States, the European Union, and Japan, Plus Fast
Supports Quoin's planned direct commercialization of QRX003 in Japan, one of its three core commerci
Four of Six Patients Participating in the Compassionate Use Program Were Classified as ‘Improved' or
-Designation provides regulatory and development incentives in Japan, including up to 10 years of ma
-First ever IND submission for this disease, which has no current treatment or cure- -Quoin plans Ph
- Filed Breakthrough Medicine Designation Application with Saudi FDA for QRX003 in Netherton Syndrom
ASHBURN, Va., April 30, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Com
Company Planning Multi-Pronged Approach for QRX009 Including Several Investigator Led Clinical Studi
Company Planning Multi-Pronged Approach for QRX009 Including Several Investigator Led Clinical Studi
FDA indicated that a single Phase 3 study may be sufficient to support marketing approval in the U.S
ASHBURN, Va., March 19, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Com
— Fast Track Designation facilitates development and expedites regulatory review of therapies addres
Videos on the NETHERTON NOW website have been viewed 2 million times with 24 million impressions ASH
Confirmation Received from MHLW That QRX003 Qualifies for Both Orphan Drug Designation and Fast Trac
QRX003 could become the first ever approved treatment for Netherton Syndrome ASHBURN, Va., Jan. 20,
Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ: QNRX - Get Free Report) saw a large decline in sh
Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarte
Shares of SOPHiA GENETICS SA (NASDAQ: SOPH) fell sharply during Tuesday’s session after the company
Companies Reporting Before The Bell • Flex LNG (NYSE:FLNG) is estimated to report earnings for its
During Thursday's session, 406 companies made new 52-week lows.
Companies Reporting Before The Bell • Vanguard Extended Duration Treasury ETF (NYSE:EDV) is estimat